Orphazyme A/S
Strategic Partners A/S does not have significant operations. Previously, it was engaged in biotech activities. The company was formerly known as Orphazyme A/S and changed its name to Strategic Partners A/S in October 2024. The company was founded in 2009 and is based in Herlev, Denmark.
Orphazyme A/S (OZYMF) - Total Liabilities
Latest total liabilities as of June 2025: $789.00K USD
Based on the latest financial reports, Orphazyme A/S (OZYMF) has total liabilities worth $789.00K USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Orphazyme A/S - Total Liabilities Trend (2013–2024)
This chart illustrates how Orphazyme A/S's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Orphazyme A/S Competitors by Total Liabilities
The table below lists competitors of Orphazyme A/S ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BioRestorative Therapies Inc
NASDAQ:BRTX
|
USA | $3.44 Million |
|
BSF Enterprise Plc
PINK:BSFAF
|
USA | $289.02K |
|
C.H.ROBINSON WLDWDE - Dusseldorf Stock Exchang
DU:CH1A
|
Germany | €3.97 Billion |
|
C.H.ROBINSON WLDWDE
HM:CH1A
|
Germany | €3.97 Billion |
|
RH Inc.
BE:RS1
|
Germany | €4.61 Billion |
|
Noratis AG
XETRA:NUVA
|
Germany | €347.30 Million |
|
ISC Fresh Water Investment SOCIMI SA
MC:YISC
|
Spain | €137.80 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Orphazyme A/S's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 19.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Orphazyme A/S's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Orphazyme A/S (2013–2024)
The table below shows the annual total liabilities of Orphazyme A/S from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $4.31 Million | -14.99% |
| 2023-12-31 | $5.07 Million | -68.02% |
| 2022-12-31 | $15.85 Million | -90.33% |
| 2021-12-31 | $163.89 Million | -18.85% |
| 2020-12-31 | $201.97 Million | +58.05% |
| 2019-12-31 | $127.78 Million | +140.65% |
| 2018-12-31 | $53.10 Million | +12.70% |
| 2017-12-31 | $47.12 Million | +226.46% |
| 2016-12-31 | $14.43 Million | +33.52% |
| 2015-12-31 | $10.81 Million | +81.15% |
| 2014-12-31 | $5.97 Million | +48.54% |
| 2013-12-31 | $4.02 Million | -- |